CO2025007987A2 - Derivados de tiadiazol como inhibidores de la sintasa de gmp-amp cíclico y usos de los mismos - Google Patents

Derivados de tiadiazol como inhibidores de la sintasa de gmp-amp cíclico y usos de los mismos

Info

Publication number
CO2025007987A2
CO2025007987A2 CONC2025/0007987A CO2025007987A CO2025007987A2 CO 2025007987 A2 CO2025007987 A2 CO 2025007987A2 CO 2025007987 A CO2025007987 A CO 2025007987A CO 2025007987 A2 CO2025007987 A2 CO 2025007987A2
Authority
CO
Colombia
Prior art keywords
inhibitors
cyclic gmp
thiadiazole derivatives
amp synthase
compounds
Prior art date
Application number
CONC2025/0007987A
Other languages
English (en)
Spanish (es)
Inventor
Jason Burch
Ramsay Beveridge
Patrick Cyr
Stephane Ciblat
Original Assignee
Ventus Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics U S Inc filed Critical Ventus Therapeutics U S Inc
Publication of CO2025007987A2 publication Critical patent/CO2025007987A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2025/0007987A 2022-12-20 2025-06-13 Derivados de tiadiazol como inhibidores de la sintasa de gmp-amp cíclico y usos de los mismos CO2025007987A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263433987P 2022-12-20 2022-12-20
US202363501320P 2023-05-10 2023-05-10
PCT/US2023/084787 WO2024137607A1 (en) 2022-12-20 2023-12-19 Thiadiazole derivatives as inhibitors of cyclic gmp-amp synthase and uses thereof

Publications (1)

Publication Number Publication Date
CO2025007987A2 true CO2025007987A2 (es) 2025-09-08

Family

ID=89768384

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2025/0007987A CO2025007987A2 (es) 2022-12-20 2025-06-13 Derivados de tiadiazol como inhibidores de la sintasa de gmp-amp cíclico y usos de los mismos

Country Status (13)

Country Link
US (1) US20240270740A1 (cg-RX-API-DMAC7.html)
EP (1) EP4638446A1 (cg-RX-API-DMAC7.html)
JP (1) JP7870987B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250131845A (cg-RX-API-DMAC7.html)
CN (1) CN120530109A (cg-RX-API-DMAC7.html)
AU (1) AU2023408761A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025001819A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025007987A2 (cg-RX-API-DMAC7.html)
IL (1) IL321525A (cg-RX-API-DMAC7.html)
MX (1) MX2025007158A (cg-RX-API-DMAC7.html)
PE (1) PE20251918A1 (cg-RX-API-DMAC7.html)
TW (1) TW202434205A (cg-RX-API-DMAC7.html)
WO (1) WO2024137607A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026077404A1 (zh) * 2024-10-10 2026-04-16 北京知维拓医药科技有限公司 一种杂环类化合物及其用途
WO2026158338A1 (zh) * 2025-01-22 2026-07-30 北京知维拓医药科技有限公司 一种杂环类化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
JP2016506408A (ja) 2012-12-19 2016-03-03 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
DK3439667T3 (da) * 2016-04-05 2024-04-02 Immune Sensor Llc Cgas antagonist forbindelser
US10738056B2 (en) * 2017-09-15 2020-08-11 Aduro Biotech Inc. Pyrazolopyrimidinone compounds and uses thereof
MX2020008237A (es) 2018-02-05 2020-09-25 Univ Rockefeller Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias.
WO2020072492A1 (en) * 2018-10-02 2020-04-09 Baruch S. Blumberg Institute Benzamide derivatives as cgas-sting pathway agonists
JP7781074B2 (ja) * 2020-05-20 2025-12-05 エフ. ホフマン-ラ ロシュ アーゲー Cgas阻害トリアゾロピリミドン誘導体
WO2022137082A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
KR20230124665A (ko) * 2020-12-22 2023-08-25 노파르티스 아게 Cgas 관련 병태의 치료에 유용한 인돌 유도체
EP4778593A2 (en) * 2021-11-08 2026-07-22 Ventus Therapeutics U.S., Inc. Heterocyclic compounds and uses thereof
CN115160279B (zh) * 2022-07-27 2023-11-24 中国药科大学 苯并吡喃酮类化合物、药物组合物和应用

Also Published As

Publication number Publication date
JP7870987B2 (ja) 2026-06-08
AU2023408761A1 (en) 2025-06-19
IL321525A (en) 2025-08-01
PE20251918A1 (es) 2025-08-05
US20240270740A1 (en) 2024-08-15
TW202434205A (zh) 2024-09-01
EP4638446A1 (en) 2025-10-29
KR20250131845A (ko) 2025-09-03
MX2025007158A (es) 2025-07-01
CN120530109A (zh) 2025-08-22
WO2024137607A1 (en) 2024-06-27
CL2025001819A1 (es) 2025-09-26
JP2026501225A (ja) 2026-01-14

Similar Documents

Publication Publication Date Title
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
CL2025001819A1 (es) Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas).
CU20110216A7 (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
CO2023000056A2 (es) Derivados de amidopirimidona
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
CR20120237A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
CL2023000387A1 (es) Derivados de dioxoloisoquinolinona novedosos y uso de los mismos
CO2024015371A2 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos
CO2025014389A2 (es) Derivados de amida para inhibir nlrp3 y usos de estos
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
MX2023011518A (es) Compuestos heterocíclicos novedosos y sus usos.
EA202192111A1 (ru) Новые тритерпеновые производные в качестве ингибиторов вич
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
BR112022004630A2 (pt) Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
CO2023010155A2 (es) Derivados de pirazolamida
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
CR20190545A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
AR131443A1 (es) Inhibidores de gmp-amp sintasa cíclica y sus usos
MX2022015532A (es) Inhibidores selectivos de hdac6 y usos de los mismos.
AR128879A1 (es) DERIVADOS DE PIRIDO-[3,4-d]PIRIDAZINA AMINA ÚTILES COMO DERIVADOS DE NLRP3